Royalty Pharma plc (RPRX): R&D Expense
$452.00M
Year ended 2025-12-31
$238.64M
Trailing 12 months to 2026-06-30
+36.7%
3-year compound annual growth
+76.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $452.00M | n/m | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $2.00M | -96.2% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $52.00M | -70.6% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $177.11M | -11.5% | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $200.08M | +661.1% | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $26.29M | -68.3% | 2023-02-15, From 2020-01-01 |
| 2019-12-31 | $83.04M | -78.9% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $392.61M | n/a | 2021-02-24, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 2025-12-31 | $452.00M | n/m |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $1.52B | +89.2% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $186.18M | -2.4% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $550.00M | +14.3% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $921.93M | +23.4% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $455.25M | -14.8% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $1.32B | +17.2% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $24.55M | +3.5% |
| Alkermes plc. (ALKS) | 2025-12-31 | $323.96M | +32.1% |
Compare RPRX, SRPT, AMRX, UTHR side by side · Screen every company in Pharmaceutical Preparations ↗